J Vis Exp. 2026 Aug 4;(234). doi: 10.3791/71128.
ABSTRACT
This study aimed to investigate the prevalence and genotype distribution of human papillomavirus (HPV) among male outpatients in Heyuan and to compare infection rates across age groups, to inform local prevention and treatment strategies. A total of 1,559 men who underwent HPV testing at Heyuan People’s Hospital between 2021 and 2024 were enrolled, and only results from initial visits were included. Twenty-three HPV genotypes were identified by polymerase chain reaction (PCR)- reverse dot blot hybridization. A retrospective cross-sectional analysis was conducted to evaluate overall HPV prevalence, age-specific infection rates, infection patterns, subtype distribution, and vaccine-relevant genotype coverage. Statistical analyses were performed using SPSS version 23.0. The count data were summarized as numbers and percentages, and group differences were assessed using the chi-square test, with statistical significance defined as p < 0.05. The overall HPV infection rate was 45.3% (707/1,559). Infection rates across age groups (≤24, 25-34, 35-44, 45-54, 55-64, and ≥65 years) were 42.8%, 43.1%, 45.8%, 48.2%, 68.3%, and 46.4%, respectively. Single-type infections were the most common pattern, accounting for 57.0% of positive cases. The five most frequently detected high-risk genotypes were HPV52 (9.05%), 16 (5.90%), 53 (5.09%), 51 (5.01%), and 59 (4.93%), while the predominant low-risk genotypes were HPV6 (21.24%), 11 (9.85%), and 43 (5.17%). The theoretical coverage rates for the bivalent, quadrivalent, and nine-valent vaccines were 8.65%, 39.74%, and 55.41%, respectively. The prevalence of HPV infection among male outpatients in Heyuan was relatively high, with single-type infections being the dominant pattern. The most common high-risk genotypes were HPV52, 16, 53, 51, and 59, and the leading low-risk genotypes were HPV6, 11, and 43. The highest infection rate was observed in the 55-64 age group. These findings provide region-specific data that may support the development of tailored HPV prevention and vaccination strategies for males in this population.
PMID:42611985 | DOI:10.3791/71128
